We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Study Reveals Basis for Development of a Universal Flu Vaccine

By LabMedica International staff writers
Posted on 26 Mar 2013
Researchers attempting to develop a "universal" flu vaccine have suggested that a multifocal approach based on primed immune cells and virus specific non-neutralizing antibodies may result in long-term protection from multiple strains of the influenza virus.

Investigators at the University of Pennsylvania (Philadelphia, USA) based their work on studies that showed that T lymphocytes were capable of mediating protection against multiple viral strains through recognition of internal, more conserved, influenza virus proteins. More...


They reported in the March 14, 2013, online edition of the journal PLOS Pathogens that influenza virus-specific CD8+ T-cells or virus-specific non-neutralizing antibodies were each relatively ineffective at conferring protective immunity alone. However, when administered together virus-specific CD8 T-cells and non-neutralizing antibodies cooperatively elicited robust protective immunity. This synergistic improvement in protective immunity was dependent, at least in part, on alveolar macrophages and/or other lung phagocytes.

“The two-pronged approach is synergistic, so by enlisting two suboptimal vaccine approaches, we achieved a better effect than each alone in an experimental model,” said senior author Dr. E. John Wherry, associate professor of microbiology at the University of Pennsylvania,. “Now, we are rethinking past approaches and looking for ways to combine T-cell vaccines and antibody vaccines to make a more effective combined vaccine. Overall, our studies suggest that an influenza vaccine capable of eliciting both CD8+ T-cells and antibodies specific for highly conserved influenza proteins may be able to provide protection in humans, and act as the basis for a potential "universal" vaccine.”

Related Links:
University of Pennsylvania



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.